BSI 709
Alternative Names: BSI-709Latest Information Update: 14 Feb 2024
Price :
$50 *
At a glance
- Originator Biosion; ImmunoGen
- Developer Biosion
- Class Antibodies; Antineoplastics; Drug conjugates; Immunotoxins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 03 Jul 2023 Biosio announces intention to submit IND application for Solid tumours in 2H 2024 (Biosion pipeline, July 2023)
- 14 Feb 2023 Preclinical trials in Solid tumours in China (Parenteral) (Biosion pipeline, February 2023)